Italy-based BMG Pharma has signed an exclusive distribution agreement with Samyang Biopharmaceutical for its novel mucositis management product, GelX.
As part of the deal, Samyang receives the rights to promote, sell and market the product in two different formulations GelX oral gel 300ml and GelX Oral spray 100ml in South Korea, as well as make an undisclosed down payment to BMG Pharma.
BMG Pharma said that GelX will help patients receive the best care possible by using a new delivery technology to provide fast pain relief and reduce swallowing issues and discomfort related with mucositis related to chemotherapy, radiotherapy and other pharmacologic therapies.
BMG Pharma president and CEO Marco Mastrodonato said: "BMG’s team were the originator of some of the major Rx medical devices in cancer supportive care, including Radiation Dermatitis and Xerostomia, and we are sure we are providing the market with a new generation of innovative products for support of cancer patients and we are very pleased of the commitment from a major company like SAMYANG for GelX."
BMG Pharma claims that the delivery technology associated with GelX is a significant breakthrough in ease of use and compliance associated with patients presenting with especially chemotherapy/radiotherapy-induced oral mucositis.
Samyang Biopharmaceutical president Cheolho Kwak said: "We are very pleased to work with BMG Pharma Srl to launch GelX in the South Korean market."
According to BMG Pharma, both GelX oral gel and spray have a mechanical action indicated for the management and relief of pain by adhering to the mucosal surface of the mouth, soothing the lesions caused by chemotherapy and/or radiation therapy.
Compared with the existing marketed products, GelX in both formulations is designated to benefit patients by improving the convenience, efficacy and compliance.